市場調查報告書
商品編碼
391454

全球OTC止痛藥市場 - 成長,趨勢,預測(2017年∼2022年)

Over the Counter (OTC) Analgesics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 108 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球OTC止痛藥市場,由於高級品牌產品的效能提高,及自有品牌產品的銷售額比例的上升等促進成長。

本報告提供全球OTC止痛藥市場相關調查,市場概要,產品類型、各地區的市場趨勢,市場規模的變化與預測,市場成長、阻礙因素以及市場機會、課題分析,市場佔有率,競爭情形,主要企業的簡介等,全面性資訊。

目錄

第1章 簡介

  • 調查的成果
  • 市場定義
  • 調查對象期間與預測
  • 一般調查的前提條件
  • 報告的說明

第2章 調查方法

  • 簡介
  • 分析方法論
  • 調查的時間軸
  • 調查的階段
    • 2次調查
    • 討論指南
    • 市場工程&計量經濟學模式

第3章 摘要整理

第4章 主要缺點

第5章 市場概要及產業趨勢

  • 市場概況
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第6章 市場動態

  • 市場成長要素
    • 高級品牌產品的效能提高
    • 高性能的PB止痛藥
  • 市場阻礙因素
    • 連續服用的副作用
  • 市場機會
    • 整合性的局部及全身治療的創新
  • 主要課題

第7章 全球OTC止痛藥市場:市場區隔

  • 藥品各類型
    • 乙醯胺酚 (Tylenol)
    • 非類固醇系抗發炎藥
    • 水楊酸鹽

第8章 全球OTC止痛藥市場:各地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙、葡萄牙
    • 斯堪地那維亞各國
    • 荷比盧三國
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲、紐西蘭
    • 韓國
    • 其他
  • 中東、非洲
    • 波灣合作理事會(GCC)
    • 南非
    • 其他
  • 南美
    • 巴西
    • 阿根廷
    • 其他

第9章 競爭情形

  • M&A分析
  • 新產品的銷售
  • 協定,合作,夥伴關係

第10章 企業簡介

  • Bayer
  • Sanofi
  • Boehringer Ingelheim
  • Novartis
  • Johnson & Johnson
  • 武田藥品
  • Sun Pharma
  • Others

第11章 分析師的投資機會預測

第12章 市場未來展望

目錄
Product Code: 52583

The over the counter (OTC) analgesics market is expected to register a CAGR of nearly 4.5% during the forecast period, with a revenue of approximately USD 25,114 million in 2020 and expected to reach USD 32,705 million by 2026.

COVID 19 pandemic is affecting the OTC market globally. The lockdown at the beginning of the pandemic has slowed the production of APIs resulting in less availability and higher costs for the materials required for the products. Over-the-counter drugs can address the mild symptoms of COVID-19 patients. Thus, OTC drugs have come into significant focus for the management of the pandemic.​

In May 2020, The European Commission has launched the European Research Area (ERA) corona platform, which will provide information associated with coronavirus research and innovation. In addition, the European Medicine Agency has recommended using non-steroidal anti-inflammatories (NSAIDs), such as ibuprofen and paracetamol, to treat mild symptoms of COVID-19 in the lowest dose form.

Furthermore, as the geriatric population is more susceptible to the infection, due to weakened immune systems, and the lack of a potential vaccine or treatment, the number of older adults suffering from coronavirus is high. Over-the-counter drugs can address the mild symptoms of COVID-19 patients. Thus, OTC drugs have come into significant focus for the management of the pandemic.​

The major factors boosting the growth of the market studied include the increasing demand in topical analgesics, growth in the geriatric population resulting in the rising prevalence of various diseases, and the cost-efficiency of OTC analgesics drugs. According to the Centers for Disease Control and Prevention, in 2019, 20.4% of adults had chronic pain and 7.4% of adults had chronic pain that frequently limited life or work activities With the growing aging population, the demand for pain relief solutions is increasing, as aged people are more prone to chronic pain.

The continuous growth of the geriatric population leads to several old age problems, for which the patients refrain from going to the hospitals, and rather get medications and treatment at home. Such factors lead to the growing importance and adoption of basic analgesics OTC products in the market. These drugs are taken for years by the older patient population, which keeps the OTC demand consistently high in the market.

The growing awareness of the internet medication in the developed nations is boosting the market growth. As per the Mitsui & Co Global Strategic Studies Institute Report 2019, in Germany, internet pharmacies gained prominence, and online sales as a percentage of total OTC drug sales in 2018 was topped with 17%, the highest in the world. Additionally, there is a high prevalence of self-medication in pregnant women in France. As per the research article published in Nursing and Midwifery Studies 2019, the overall prevalence rate of self-medication was 38.46%. The rising prevalence of self-medication will propel the overall market growth.

According to the article published in Current Clinical Pharmacology, in November 2019, overall mean prevalence of self medication practices in India was 53.57%. Awareness of the medication seems to be a major reason to practice self medication , and the practice was noticed more among individuals from a middle-lower class family with a prevalence rate of 26.31. Furthermore, minor ailments were the primary reason for SM, among which headache was the most commonly reported

OTC medicines help fulfill a growing consumer appetite for self care. Due to these multiple benefits, the increase in self medication is likely to continue to drive the growth of the market during the forecast period

Key Market Trends

Retail Pharmacies Segment by Distribution Channel is Expected to Dominate the Market

In today's scenario, the public is increasingly adopting retail pharmacy as a one-stop-shop to buy all the over-the-counter products which can be useful at home, and OTC products along with analgesics are one of the important parts of this distribution channel segment. The fact that a large number of a growing population cannot afford to reach hospitals to check up on a regular basis and need the OTC products quickly, raises the demand for this segment. Furthermore, most of the patients are preferring self-medication without consulting a doctor or a pharmacist. However, the hospital pharmacies segment is expected to maintain a relatively low growth rate in terms of revenue generated through the distribution of OTC drugs, as mostly the sale of OTCs takes place in the case of non-prescribed drugs, and it is relatively easy for most consumers to acquire these drugs either from retail pharmacies or online pharmacies. Thus, owing to the rising geriatric population, affordability, and high accessibility of OTC analgesics, the market is expected to witness rapid growth over the forecast period. Moreover, the pandemic and the lockdowns dint affect the segment as many countries even during the lockdowns had retail pharmacies open for emergency usage mostly.

North America is Expected to Dominate the Market

According to the Consumer Healthcare Products Association, 2019, it is estimated that approximately 93% of Americans choose to treat their minor ailments with OTC medications before seeking professional care. Chronic pain is linked to a number of physical and psychological conditions, and contributes to the high cost of health care and lost productivity. Both types of pain were more prevalent in poor adults, undergraduate adults, and adults with public health insurance. For the treatment of muscle injuries and disorders, many patients in the United States usually use ineffective analgesics. Hence, with the increase in the prevalence of chronic pain, the demand for OTC analgesics is expected to increase, which is likely to drive the market over the forecast period. However, according to the Food and Drug Administration (FDA) 2020, due to the recent corona virus outbreak (COVID 19) in this country and the shortage of drug supply the market is expected to face challenges in near future.

Competitive Landscape

The market studied is fragmented in nature, owing to the presence of many small and large market players. Some of the major players are Bayer AG, Boehringer Ingelheim International GmbH, Johnson & Johnson, GlaxoSmithKline PLC, Pfizer Inc., Reckitt Benckiser Group PLC, Sanofi SA, Sun Pharmaceutical Industries Ltd, and Takeda Pharmaceutical Company Limited.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Demand in Topical Analgesics
    • 4.2.2 Growth in the Geriatric Population Resulting in the Rising Prevalence of Various Diseases
    • 4.2.3 Cost Efficiency of OTC Analgesics Drugs
  • 4.3 Market Restraints
    • 4.3.1 Drug Tolerance, Dependence, and Addiction and Abuse​
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type of Drug
    • 5.1.1 Acetaminophen
    • 5.1.2 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • 5.1.3 Salicylates
    • 5.1.4 Other Analgesics​
  • 5.2 By Distribution Channel
    • 5.2.1 Hospital Pharmacies
    • 5.2.2 Retail Pharmacies
    • 5.2.3 Online Pharmacies
    • 5.2.4 Others Distribution Channels
  • 5.3 By Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Bayer AG
    • 6.1.2 Boehringer Ingelheim International GmbH
    • 6.1.3 Johnson & Johnson
    • 6.1.4 GlaxoSmithKline PLC
    • 6.1.5 Pfizer Inc.
    • 6.1.6 Reckitt Benckiser Group PLC
    • 6.1.7 Sanofi SA
    • 6.1.8 Sun Pharmaceutical Industries Ltd
    • 6.1.9 Takeda Pharmaceutical Company Limited
    • 6.1.10 AstraZeneca PLC
    • 6.1.11 Merck & Co Inc.
    • 6.1.12 Novartis AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS